Category:Cutaneous adverse effects of antimelanoma therapies

Media in category "Cutaneous adverse effects of antimelanoma therapies"

The following 14 files are in this category, out of 14 total.

• 
  Lymphatic (DermNet NZ lesions-metastatic-melanoma08).jpg 640 × 480; 103 KB
  
• 
  Oral lichen planus due to nivolumab (DermNet NZ lichenoid-oral-nivolumab).jpg 640 × 426; 49 KB
  
• 
  Cutaneous (DermNet NZ metastatic-melanoma-13).jpg 640 × 480; 119 KB
  
• 
  Nivolumab-induced lichenoid dermatitis (DermNet NZ nivolumab-lichenoid-1).jpg 640 × 480; 50 KB
  
• 
  Nivolumab-induced lichenoid dermatitis (DermNet NZ nivolumab-lichenoid-2).jpg 640 × 480; 72 KB
  
• 
  Panniculitis due to vemurafenib (DermNet NZ panniculitis-vemurafenib-v2).jpg 640 × 480; 39 KB
  
• 
  Eczema induced by pembrolizumab (DermNet NZ pembrolizumab-eczema-04).jpg 640 × 480; 117 KB
  
• 
  Bullous pemphigoid induced by pembrolizumab (DermNet NZ pembrolizumab-pemphigoid-01).jpg 480 × 640; 95 KB
  
• 
  Psoriasis induced by pembrolizumab (DermNet NZ pembrolizumab-psoriasis-5).jpg 1,998 × 1,499; 685 KB
  
• 
  Drug hypersensitivity syndrome caused by vemurafenib (DermNet NZ rash-vemurafeniba).jpg 480 × 640; 77 KB
  
• 
  Alopecia due to vemurafenib (DermNet NZ reactions-egfri-alopecia).jpg 640 × 480; 129 KB
  
• 
  Keratoderma due to vemurafenib (DermNet NZ reactions-egfri-scale).jpg 640 × 480; 75 KB
  
• 
  Folliculitis due to vemurafenib (DermNet NZ reactions-vemurafenib-folliculitis).jpg 428 × 480; 53 KB
  
• 
  Papilloma due to vemurafenib (DermNet NZ reactions-vemurafenib-papilloma1).jpg 640 × 480; 79 KB